Table 4– Serious complications in endobronchial valve (EBV) therapy and control patients (0–386 days)

Event	Up to 3 months (<97 days)			3–6 months (98–194 days)			6–9 months (195–284 days)			9–12 months (285–386 days)
	EBV therapy	Control	p-value	EBV therapy	Control	p-value	EBV therapy	Control	p-value	EBV therapy	Control	p-value
Patients n	111	60		111	60		111	60		111	60
Death	1 (0.9)	1 (1.7)	1.00	2 (1.8)	0	0.54	2 (1.8)	0	0.54	1 (0.9)	3 (5.0)	0.12
Respiratory failure	4 (3.6)	1 (1.7)	0.66	3 (2.7)	3 (5.0)	0.42	3 (2.7)	1 (1.7)	1.00	0	1 (1.7)	0.35
≥24 h ventilation	2 (1.8)	0	0.54	2 (1.8)	1 (1.7)	1.00	3 (2.7)	0	0.55	0	1 (1.7)	0.35
Haemoptysis	6 (5.4)	1 (1.7)	0.42	4 (3.6)	0	0.30	1 (0.9)	0	1.00	3 (2.7)	0	0.55
Massive	0	0		1 (0.9)	0	1.00	0	0		0	0
Pneumothorax or air leak	5 (4.5)	0	0.16	1 (0.9)	0	1.00	1 (0.9)	0	1.00	2 (1.8)	0	0.54
>7 days	4 (3.6)	0	0.30	1 (0.9)	0	1.00	1 (0.9)	0	1.00	0	0
Empyema	0	0		0	0		0	0	1.00	0	0
Pneumonia not distal to valve	4 (3.6)	1 (1.7)	0.66	2 (1.8)	0	0.54	4 (3.6)	1 (1.7)	0.66	3 (2.7)	0	0.55
Pneumonia distal to valve	4 (3.6)			2 (1.8)			0			1 (0.9)	0
COPD exacerbation	47 (42.3)	28 (46.7)	0.63	36 (32.4)	19 (31.7)	1.00	16 (14.4)	9 (15.0)	1.00	17 (15.3)	12 (20.0)	0.52
With hospitalisation	13 (11.7)	6 (10.0)	0.80	13 (11.7)	7 (11.7)	1.00	12 (10.8)	3 (5.0)	0.26	4 (3.6)	2 (3.3)	1.00
Without hospitalisation	31 (27.9)	23 (38.3)	0.17	21 (18.9)	13 (21.7)	0.69	6 (5.4)	6 (10.0)	0.35	13 (11.7)	10 (16.7)	0.36

Data are presented as n (%), unless otherwise stated. COPD: chronic obstructive pulmonary disease.